Oncolytics Says FDA Interactions May Allow REO 033 Study Expansion
Oncolytics said FDA interactions may allow a pivotal expansion of its REO 033 study in second-line RAS-mutant MSS metastatic colorectal cancer. The company said the expansion could support accelerated approval based on objective response rate and full approval based on progression-free survival.